Pharmacology Research and Perspectives This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Information overdose: Student performance and perceptions of pharmacology resources on exams
Overview of curriculum and timeline of data collection. Data collection started in F1 in 2017 and the study cohort completed the final survey in 2021. AbstractPhysicians of the future will be expected to synthesize new knowledge and appropriately apply it in patient care. Here, we report on the effects of and student attitudes towards resource-enhanced exams by comparing student performance on closed-book exams with or without access to pharmacology flashcards. Setting: the University of California, San Francisco (UCSF) School of Medicine (SOM), class of 2021 (N = 149), followed over 4 years. We provided pharmacology...
Source: Pharmacology Research and Perspectives - April 21, 2023 Category: Drugs & Pharmacology Authors: Marieke Kruidering ‐Hall, Rupa Lalchandani Tuan Tags: ORIGINAL ARTICLE Source Type: research

Absorption, metabolism, and excretion of [14C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis. Studies evaluating absorption, distribution, metabolism, and excretion (ADME) demonstrated dersimelagon is extensively metabolized to the glucuronide in the liver, which is eliminated in bile, and hydrolyzed to unchanged dersimelagon in the gut. The primary route of excretion was feces. Major metabolites detected in human feces and plasma as we...
Source: Pharmacology Research and Perspectives - April 20, 2023 Category: Drugs & Pharmacology Authors: Minoru Tsuda, Kei Ogawa, Tadashi Endou, Takahiro Goto, Yuko Ogasawara, Akihito Ogasawara Tags: ORIGINAL ARTICLE Source Type: research

Computational design and molecular modeling of morphine derivatives for preferential binding in inflamed tissue
The fluorinated morphine derivatives target binding prefentially with inflamed tissue, while being deterred from binding within central tissues such as the brain. Binding within the brain results in the addictive and dangerous side effects associated with opioid use; however, targetted binding in inflamed tissue will result in pain relief without the addictive component. AbstractThe opioid epidemic has impacted over 10  million Americans in 2019. Opioids, like morphine, bind non-selectively in both peripheral tissue, leading to effective pain relief, and central tissue, resulting in dangerous side effects and addiction. T...
Source: Pharmacology Research and Perspectives - April 20, 2023 Category: Drugs & Pharmacology Authors: Makena Augenstein, Nayiri Alexander, Matthew Gartner Tags: ORIGINAL ARTICLE Source Type: research

Issue Information
(Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 19, 2023 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID ‐19
(Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - April 11, 2023 Category: Drugs & Pharmacology Authors: Rodolfo Pedro Rothlin, Facundo Germ án Pelorosso, Mariano Duarte, Liliana Nicolosi, Fernandez Criado Ignacio, María Victoria Salgado, Héctor Vetulli Tags: COMMENTARY Source Type: research

The N ‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
Coadministration of inclisiran and atorvastatin in cynomolgus monkeys significantly inhibited proprotein convertase subtilisin/kexin type 9 synthesis and decreased low-density lipoprotein cholesterol with no adverse toxicokinetic or pharmacodynamic effects. AbstractInclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low-density lipoprotein cholesterol (LDL-C) by ≥50% in patients with hypercholesterolemia receiving maximally tolerated statins. The toxicokinetic, pharmacodynamic, and safety profiles of inclisiran...
Source: Pharmacology Research and Perspectives - April 7, 2023 Category: Drugs & Pharmacology Authors: Dario Lehoux, David Kallend, Peter L. J. Wijngaard, Alan P. Brown, Brad Zerler Tags: ORIGINAL ARTICLE Source Type: research

Risk of antidepressant initiation among users of cardiovascular agents and metformin.
This study aimed to examine possible associations between the use of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEI), acetylsalicylic acid (ASA), beta-blockers (BB), calcium channel blockers (CCB), diuretics, or metformin and risk of antidepressant initiation. The Tr øndelag Health Study (HUNT3), Norway, was linked to the Norwegian Prescription Database (NorPD). Participants with no prescriptions of cardiovascular agents, metformin, or antidepressants for at least 6 months before HUNT3 (baseline) were eligible and followed for 10 years. The exposure was the use of cardiovascula...
Source: Pharmacology Research and Perspectives - April 5, 2023 Category: Drugs & Pharmacology Authors: Ivana Bojani ć, Ottar Bjerkeset, Lana J. Williams, Michael Berk, Johan Håkon Bjørngaard, Erik R. Sund, Hege Sletvold Tags: ORIGINAL ARTICLE Source Type: research

Tetrahydrocurcumin Add ‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
In this study, diabetic chronic kidney disease (CKD) rats received tetrahydrocurcumin with a lipid carrier polyenylphosphatidylcholine (THC/PPC) as add-on therapy to losartan. Kidney fibrosis, glomerulosclerosis, and tubulointerstitial injury were increased in diabetic CKD rats. The fibrosis level was reduced after treatment with THC/PPC, and the tubulointerstitial injury level was decreased with THC/PPC/losartan treatment. Moreover, THC/PPC/losartan treatment lowered blood pressure, improved the expression of antioxidants such as catalase and CuZnSOD, and reduced the levels of protein kinase C- α, kidney injury molecule-...
Source: Pharmacology Research and Perspectives - March 27, 2023 Category: Drugs & Pharmacology Authors: Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaeli, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau Tags: ORIGINAL ARTICLE Source Type: research

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid ‐associated abuse, dependence, or withdrawal
AbstractSpontaneous reporting is based on the experience of all healthcare professionals (HCPs) but also consumers/non-HCPs and therefore reveals a broad picture of a drug's adverse reactions. Recent studies found substantial differences between reports from these varying sources including the reports' completeness. Using the example of opioid-associated abuse, dependence, or withdrawal, this study analyzed the completeness and characteristics of spontaneous reports from Germany focusing on the reporter. Based on EudraVigilance data, we included all cases of abuse, dependence, or withdrawal associated with opioids indicate...
Source: Pharmacology Research and Perspectives - March 25, 2023 Category: Drugs & Pharmacology Authors: Kathrin Jobski, Carsten Bantel, Falk Hoffmann Tags: SHORT REPORT Source Type: research

Cognitive and negative symptoms in schizophrenia with L ‐Carnosine adjuvant therapy – A randomized double‐blind placebo‐controlled study
AbstractThe antioxidant L-Carnosine is reported to improve negative and cognitive symptoms in Schizophrenia. A randomized double-blind placebo-controlled study was planned to study the effectiveness of adjuvant L-Carnosine therapy in patients with Schizophrenia. 100 eligible patients with predominant negative symptoms as measured by scale for assessment of negative symptoms (SANS total score  ≥ 60) and Schizophrenia diagnosis (International Classification of Disorder-Tenth Edition, ICD-10) were recruited. They were randomly allocated to receive a fixed dose of either 400 mg L-Carnosine or identical placebo for 3�...
Source: Pharmacology Research and Perspectives - March 25, 2023 Category: Drugs & Pharmacology Authors: Hema Tharoor, Sindhu Maran, Antra K. Chandan, Manikandan Pari, Shruti Rao, Jothilakshmi Durairaj Tags: ORIGINAL ARTICLE Source Type: research